Because SjD patients exhibit many hallmarks of B cell hyperactivity, including the development of anti-SSA/Ro autoantibodies, the presence of ectopic germinal centers in the salivary glands, and increased risk of B cell lymphoma (5, 7, 8), B cell-targeted therapies have also been utilized to treat systemic symptoms of SjD. This evidence concerns the gene CALR and B-cell non-Hodgkin lymphoma.